- The FDA has granted 510(k) clearance for Apyx Medical Corporation's APYX Renuvion for subcutaneous dermatological and aesthetic procedures to improve the appearance of lax skin in the neck and submental region.
- Renuvion is a proprietary helium plasma and radiofrequency technology.
- Related: Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin.
- This clearance offers a new option for physicians and patients to improve loose skin on the neck and submental region.
- With this clearance, Renuvion is the only product that is FDA-cleared to improve the appearance of loose skin on the neck and chin.
- Renuvion provides a minimally-invasive and cost-effective option with minimal downtime. The results reveal a more contoured and smoother neck and jawline.
- Price Action: APYX shares are up 9.20% at $8.31 during the market session on the last check Monday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in